# Resource Summary Report

Generated by dkNET on Aug 16, 2026

## Mouse Anti-Human Bcl-2 (100) Monoclonal, Unconjugated, Clone 100

RRID:AB_626733
Type: Antibody

### Proper Citation

Santa Cruz Biotechnology Cat# sc-509, RRID:AB_626733

### Antibody Information

**URL:** http://antibodyregistry.org/AB_626733

**Proper Citation:** Santa Cruz Biotechnology Cat# sc-509, RRID:AB_626733

**Target Antigen:** Human BCL2

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** validation status unknown check with seller; recommendations: Flow Cytometry; Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Immunoprecipitation; Western Blot; Western Blotting, Immunoprecipitation, Immunofluorescence, Immunohistochemistry(P), Flow Cytometry

**Antibody Name:** Mouse Anti-Human Bcl-2 (100) Monoclonal, Unconjugated, Clone 100

**Description:** This monoclonal targets Human BCL2

**Target Organism:** human

**Clone ID:** 100

**Antibody ID:** AB_626733

**Vendor:** Santa Cruz Biotechnology

**Catalog Number:** sc-509

**Record Creation Time:** 20250820T034422+0000

**Record Last Update:** 20250820T170325+0000

## Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human Bcl-2 (100) Monoclonal, Unconjugated, Clone 100.

No alerts have been found for Mouse Anti-Human Bcl-2 (100) Monoclonal, Unconjugated, Clone 100.

## Data and Source Information

**Source:** Antibody Registry

## Usage and Citation Metrics

We found 16 mentions in open access literature.

**Listed below are recent publications.** The full list is available at dkNET .


Fiskus W, et al. (2025) Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood, 145(6), 612.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Meril S, et al. (2024) Loss-of-function cancer-linked mutations in the EIF4G2 non-canonical translation initiation factor. Life science alliance, 7(3).

van Gemert F, et al. (2024) ADARp150 counteracts whole genome duplication. Nucleic acids research, 52(17), 10370.

Ming Z, et al. (2023) IFN-? Signaling Sensitizes Melanoma Cells to BH3 Mimetics. The Journal of investigative dermatology, 143(7), 1246.

Fiskus W, et al. (2022) Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood cancer journal, 12(1), 5.

Abo El Gheit RE, et al. (2022) Melatonin epigenetic potential on testicular functions and fertility profile in varicocele rat model is mediated by silent information regulator 1. British journal of pharmacology, 179(13), 3363.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer discovery, 12(3), 752.

Prew MS, et al. (2022) MCL-1 is a master regulator of cancer dependency on fatty acid oxidation. Cell reports, 41(1), 111445.

Lafferty A, et al. (2021) Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(21), 5979.

Mohankumar K, et al. (2020) Bis-Indole-Derived Nuclear Receptor 4A1 (NR4A1, Nur77) Ligands as Inhibitors of Endometriosis. Endocrinology, 161(4).

Campos JC, et al. (2020) ?2 -adrenoceptor activation improves skeletal muscle autophagy in neurogenic myopathy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 34(4), 5628.

Elkholi R, et al. (2019) MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network. Molecular cell, 74(3), 452.

Fiskus W, et al. (2019) Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood cancer journal, 9(2), 4.

Benedict B, et al. (2018) Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells. eLife, 7.

Muñoz-Moreno L, et al. (2018) Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. The Prostate, 78(12), 915.